Novartis Ag

Latest Stories

This undated image provided by Novartis shows bottles of Novartis’s Adakveo. U.S. regulators have approved the new sickle cell disease medicine that can prevent extremely painful, dangerous “crises” in which misshapen blood cells clump together, reducing blood and oxygen flow. (Novartis via AP)

US approves new drug to manage sickle cell disease

By LINDA A. JOHNSON - Associated Press

This photo provided by Novartis shows their gene therapy medicine Zolgensma. U.S. regulators want to know why Novartis didn't disclose a problem with testing data until after they approved the Swiss drugmaker’s $2.125 million gene therapy. On Tuesday, Aug. 6, 2019, the Food and Drug Administration said the questionable data involves testing of the therapy, Zologensma, on animals, not on patients. (Novartis via AP)

FDA says Novartis withheld data problem before drug approval

By LINDA A. JOHNSON - Associated Press

Novartis AG buys Indiana biotech startup Endocyte for $2.1B

Associated Press

FDA OKs new Novartis drug for type of advanced breast cancer

By BY LINDA A. JOHNSON - Associated Press

In this Monday, Nov. 23, 2015, photo, flags fly in front of Pfizer World Headquarters, in New York. Drugmaker Pfizer said that in November 2016 it will launch a less-expensive version of rival Johnson &amp; Johnson’s blockbuster immune disorder drug, Remicade. Pfizer’s version, called Inflectra, will hit pharmacies in late November. It will be only the second so-called biosimilar drug available in the U.S. (AP Photo/Mark Lennihan)

Pfizer to launch cheaper version of J&J immune drug Remicade

By LINDA A. JOHNSON - Associated Press

Pfizer ups offer for AstraZeneca again, to $119B

By LINDA A. JOHNSON - Associated Press

FILE - The Oct. 19, 2012 file photo shows a Novartis employee in a laboratory of Novartis in Prangins near Nyon, Switzerland. Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday, April 22, 2014 with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally. (AP Photo/Keystone, Yannick Bailly)

Novartis reshapes business with GSK, Lilly deals

By JOHN HEILPRIN - Associated Press

** FILE ** In this Thursday, Feb. 9, 2012, file photo, a pharmacist works in a lab where medicines are being produced at a Cipla manufacturing unit on the outskirts of Mumbai, India. A lawyer for healthcare activists says India's Supreme Court has rejected drug maker Novartis AG' right to patent a new version of a lifesaving cancer drug. (AP Photo/Rafiq Maqbool, File)

Drug maker Novartis loses India patent battle

By Nirmala George - Associated Press

** FILE ** In this March 13, 2012, file photo, Indian scientists work inside a laboratory of the Research and Development Centre of Natco Pharma Ltd. in Hyderabad, India. (AP Photo/Mahesh Kumar A., File)

Indian court to rule on generic drug industry

By Nirmala George - Associated Press

Indian court to rule on generic drug industry

By NIRMALA GEORGE - Associated Press

EU drug regulator OKs Novartis’ meningitis B shot

By ASSOCIATED PRESS - Associated Press

EU approves Afinitor for certain breast cancers

By ASSOCIATED PRESS - Associated Press

New drugs shore up Novartis in Q2

By FRANK JORDANS - Associated Press

Novartis tries to make UK hospitals use $1000 drug

By MARIA CHENG - Associated Press

Novartis drug investigated after 11 deaths

By ASSOCIATED PRESS - Associated Press

Big promise is seen in 2 new breast cancer drugs

By MARILYNN MARCHIONE - Associated Press

Novartis fights patent rejection in Indian court

By KATY DAIGLE - Associated Press

Novartis receives OK to market eye drug in Europe

By ASSOCIATED PRESS - Associated Press

Correction: Breast Cancer-Bone Drug story

By ASSOCIATED PRESS - Associated Press

Bone drug Zometa flops in breast cancer study

By MARILYNN MARCHIONE - Associated Press